Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates.

Antimicrobial agents and chemotherapy - 16 Jul 2021

Mok Simone, Roycroft Emma, Flanagan Peter R, Montgomery Lorraine, Borroni Emanuele, Rogers Thomas R, Fitzgibbon Margaret M

Abstract excerpt

Pyrazinamide (PZA) is one of the first-line agents used for the treatment of tuberculosis. However, current phenotypic PZA susceptibility testing in the Bactec MGIT 960 system is unreliable, and false resistance is well documented. Rapid identification of resistance-associated mutations can confirm the phenotypic result. This study aimed to investigate the use of genotypic methods in combination with phenotypic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amidohydrolases
Share to Antitubercular Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Bacterial

Share to Microbial Sensitivity Tests

Share to Mutation

Share to Mycobacterium tuberculosis

Share to Pyrazinamide

Share to Tuberculosis Research and Epidemiology

Source

Open in PubMed Open full text

Identifiers

PMID: 33972244
DOI: 10.1128/AAC.02617-20
PMCID: PMC8284449

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates.PMID 33972244Read ↗

Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Hangzhou, China.Semantic proximity Read ↗

High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in Mycobacterium tuberculosis isolates from Uganda.Semantic proximity Read ↗

Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients.Semantic proximity Read ↗

Non-pncA Gene-Mutated but Pyrazinamide-Resistant Mycobacterium tuberculosis: Why Is That?Semantic proximity Read ↗

Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis.Semantic proximity Read ↗

Detection of Pyrazinamide Heteroresistance in Mycobacterium tuberculosis.Semantic proximity Read ↗

Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study.Semantic proximity Read ↗

Genotypic characterization of pyrazinamide resistance in Mycobacterium tuberculosis isolated from Lusaka, Zambia.Semantic proximity Read ↗

Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates: pncA sequencing versus Bactec MGIT 960.Semantic proximity Read ↗

Genotypic Resistance of Pyrazinamide but Not Minimum Inhibitory Concentration Is Associated With Longer Time to Sputum Culture Conversion in Patients With Multidrug-resistant Tuberculosis.Semantic proximity Read ↗

Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.Semantic proximity Read ↗

Pyrazinamide Susceptibility and pncA Mutation Profiles of Mycobacterium tuberculosis among Multidrug-Resistant Tuberculosis Patients in Bangladesh.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.